Astellas Pharma (China)

Recent papers from Astellas Pharma (China)

1. From Real World Data to Real Impact: A Co‐Medication Framework for Lung Cancer to Advance DDI Assessment and Patient‐Centric Drug DevelopmentClinical and Translational Science · 2026
2. Multilevel Network Meta‐Regression With a Survival Outcome and an Application to Non‐Small Cell Lung CancerStatistics in Medicine · 2026
3. Physiologically based pharmacokinetic (PBPK) model to predict the magnitude of drug-drug interaction between vincristine and the azole antifungals isavuconazole, posaconazole, and voriconazole in childrenAntimicrobial Agents and Chemotherapy · 2026
4. AWAVM-UNet: adaptive-weighted attention VM-UNet with multiscale attention feature aggregation for grape disease detection from UAV imageryFrontiers in Plant Science · 2026
5. Advancing sustainable energy transitions in small island developing states: Lessons from the clean cooking strategy of São Tomé and PríncipeEnergy Sustainable Development/Energy for sustainable development · 2026
6. ASP2998, a trophoblast cell-surface antigen 2 (TROP2)–targeted immunostimulatory antibody-drug conjugate with dual payloads, in patients with locally advanced unresectable or metastatic solid tumors: A phase 1b/2 study.Journal of Clinical Oncology · 2026
7. Efficacy and safety of enzalutamide (ENZA) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) and cardiometabolic comorbidities (CMDs) and/or related concomitant medications (meds): ARCHES post hoc.Journal of Clinical Oncology · 2026
8. Diastereomer separation of phosphorothioate oligonucleotides via conformationally stabilizing ion pairs in reversed-phase liquid chromatographyJournal of Chromatography A · 2026
9. Gilteritinib + chemotherapy in children with relapsed/refractory FLT3-ITD AML: results from the phase 1/2 SKIPPER trial.2026
10. Enfortumab vedotin plus pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: results from EV-202 cohort 9Clinical Cancer Research · 2026
11. Treatment Persistence and Adherence with Overactive Bladder Medications in Taiwan: A Retrospective Database AnalysisEuropean Urology Open Science · 2026
12. A Seamless Two‐Stage Phase I/ II Trial Design With Backfill and Joint Monitoring for Dose OptimizationPharmaceutical Statistics · 2026
13. Pharmacological Rescue of Follicle-Stimulating Hormone Receptor Mutants. In vitro and In silico StudiesEndocrinology · 2026
14. Targeted literature review of concepts related to women’s experiences and perceptions of vasomotor symptoms associated with menopauseMenopause The Journal of The North American Menopause Society · 2025
15. A phase I/II study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia: final analysisTherapeutic Advances in Hematology · 2026
16. Phase 2 study of ASP5541 (PRL-02), a long-acting intramuscular depot injection of abiraterone decanoate, in patients with advanced prostate cancer.Journal of Clinical Oncology · 2026
17. Outcomes of patients with R/R FLT3mut+ AML treated with maintenance gilteritinib therapy after hematopoietic stem cell transplantationLeukemia Research · 2026
18. Real-world disease characteristics and frontline treatments used in chronic lymphocytic leukaemia in Bulgaria: An observational cohort study (DESCRIBE)Journal of International Medical Research · 2026
19. Treatment patterns of hormone therapy for menopause-associated vasomotor symptoms: analysis of the HIRA database in South KoreaClimacteric · 2026
20. Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumorsJournal for ImmunoTherapy of Cancer · 2026